title: Drug management of Parkinson's disease.
abstract: Levodopa remains the cornerstone for managing Parkinson's disease. Physician's preference usually determines the dopamine agonist chosen for the early phases of treatment. The concept of neuro-protection, however, remains unproven. A better understanding of the cause of the disease and treatment-related complications could make managing Parkinson's disease more rewarding.
authors.affiliation: Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre, BC.
authors.forename: A
authors.initials: A
authors.lastname: Kishore
authors.forename: B J
authors.initials: BJ
authors.lastname: Snow
mesh_terms: D000547:Amantadine / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000145:classification / Q000627:therapeutic use*; D001971:Bromocriptine / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000209:etiology; D012642:Selegiline / Q000627:therapeutic use; D014282:Trihexyphenidyl / Q000627:therapeutic use
chemical_list: D000978:Antiparkinson Agents; D012642:Selegiline; D001971:Bromocriptine; D007980:Levodopa; D014282:Trihexyphenidyl; D000547:Amantadine